171 patents
Page 5 of 9
Utility
DNA methylation diagnostic test for breast cancer
8 Feb 22
The present subject matter provides, inter alia, a method of diagnosing invasive ductal cancer or detecting invasive ductal cancer risk in a subject who has ductal carcinoma in situ, a method of treating breast cancer in a subject detected to have invasive ductal cancer or determined to be at risk of invasive ductal cancer, compositions for detecting invasive presence or potential in ductal carcinoma in situ in a subject, and kits including reagents and composition for detecting invasive presence or potential in ductal carcinoma in situ in a subject.
Maria A. Hahn, John H. Yim, Yuman Fong, Arthur X. Li, Xiwei Wu, Sun-Wing T. R. Tong
Filed: 28 Dec 18
Utility
RNA aptamers against transferrin receptor (TFR)
1 Feb 22
Provided herein, inter alia, are nucleic acid compounds capable of binding transferrin receptor on a cell and internalizing into said cell.
John J. Rossi, Sorah Yoon, Nagy Habib
Filed: 15 Oct 15
Utility
Synthesis of ETP derivatives
25 Jan 22
David Horne, Jun Xie
Filed: 22 May 18
Utility
Chimeric antigen receptors containing a chlorotoxin domain
25 Jan 22
Chimeric transmembrane immunoreceptors (CAR) which include an extracellular domain that includes chlorotoxin or a related toxin, or a variant of chlorotoxin or a related toxin, that binds to human glioma or other human tumor cells, a transmembrane region, a costimulatory domain and an intracellular signaling domain are described.
Michael Barish, Christine E. Brown, Stephen J. Forman, Dongrui Wang
Filed: 13 Oct 16
Utility
P38 map kinase inhibitors
18 Jan 22
Provided herein, inter alia, are p38 mitogen-activated protein kinase inhibitors and methods of treating cancer using p38 mitogen-activated protein kinase inhibitors.
John J. Rossi, Sorah Yoon
Filed: 15 Jun 20
Utility
Bi-specific aptamer
11 Jan 22
Provided are aptamers and aptamer compositions and particularly, although not exclusively, to a bi-specific aptamer capable of binding a tumor cell antigen and an immune cell surface protein.
John J. Rossi, Sorah Yoon, Nagy Habib
Filed: 17 Feb 17
Utility
Thioindirubins
4 Jan 22
Disclosed herein inter alia are compositions and methods for treating cancer using thioindirubin derivatives.
Sangkil Nam, David Horne, Ravi Salgia, Alexios Leandros Skaltsounis, Nicolas Gaboriaud-Kolar, Panagiotis Gerolymatos, Nikolaos Lougiakis
Filed: 30 Aug 18
Utility
Methods and compositions for the treatment of cancer or other diseases
28 Dec 21
The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases.
Hua Yu, Marcin Kortylewski, Richard Jove, Piotr Marek Swiderski, John J. Rossi
Filed: 6 Mar 19
Utility
Chimeric antigen receptors targeting HER2
14 Dec 21
Chimeric transmembrane immunoreceptors (CAR) which include an extracellular domain targeted to HER2, a transmembrane region, a costimulatory domain and an intracellular signaling domain are described.
Saul J. Priceman, Stephen J. Forman, Christine E. Brown
Filed: 4 Nov 16
Utility
DNA2 inhibitors for cancer treatment
14 Dec 21
Disclosed herein, inter alia, are compositions and methods for inhibiting DNA2.
Binghui Shen, Judith Campbell, Li Zheng, Hongzhi Li, David Horne, Jun Xie, Kenneth Karanja
Filed: 13 Jan 20
Utility
Silica nanoparticle with an insoluble drug
7 Dec 21
Disclosed herein, inter alia, are nanoparticle compositions (e.g., silica nanoparticles) including insoluble drug nanocrystals and methods of using the same for treating cancer.
Pamela Tiet, Jacob Berlin
Filed: 2 Feb 18
Utility
Development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies
30 Nov 21
In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof.
John C. Williams, Ulrich Rodeck, Joshua M. Donaldson, Csaba Kari
Filed: 22 Feb 17
Utility
CTLA-4 aptamer conjugates
30 Nov 21
Provided herein are, inter alia, nucleic acid compounds useful for targeting CTLA-4-expressing cells and modulating cell activity of the CTLA-4-expressing cells.
Hua Yu, Andreas Herrmann, Marcin Tomasz Kortylewski
Filed: 4 Jun 20
Utility
IL-6 signaling and breast cancer
30 Nov 21
The disclosure provides, inter alia, methods of detecting IL-6 signaling activity in T cells in breast cancer patients, such as breast cancer patients in remission.
Peter P. Lee
Filed: 22 Oct 19
Utility
Methods of quantifying N
23 Nov 21
Methods of quantifying a N2-(1-carboxyethyl)-2′-deoxyguanosine (CEdG) levels in biological samples and comparing those levels to known normal levels can diagnose a number of metabolic disorders or complications associated therewith, including diabetes, its associated complications, and cancer.
Samuel Rahbar, Timothy W. Synold, John Termini, Gerald Wuenschell, Daniel Tamae
Filed: 2 Feb 18
Utility
PDGFR RNA aptamers
23 Nov 21
Provided herein, inter alia, are nucleic acid compounds capable of binding PDGFR-a on a cell and internalizing into said cell.
John J. Rossi, Sorah Yoon, Nagy Habib
Filed: 15 Oct 15
Utility
Hand-held grasping device
16 Nov 21
A hand tool has a pivot connection pivotally attaching a first arm to a second arm, with the pivot connection fixed relative to the first arm and movable to first and second positions relative to the second arm.
David Wong, Anthony Le, Gagandeep Singh, H. Lawson Fisher, James McCrea
Filed: 20 Aug 15
Utility
FOXM1 modulators and uses thereof
9 Nov 21
Disclosed herein, inter alia, are FOXM1 modulators and methods for modulating the activity of androgen receptors in neuronal cells to treat various diseases, such as spinal-bulbar muscular atrophy, amyotrophic lateral sclerosis, and Alzheimer's disease.
Jeremy Jones, Maya Otto-Duessel
Filed: 1 Aug 17
Utility
BAFF-R targeted chimeric antigen receptor-modified t-cells and uses thereof
2 Nov 21
Provided herein are T cells expressing a chimeric antigen receptor (CAR) targeted to B cell activating factor receptor (BAFF-R).
Hong Qin, Larry W. Kwak
Filed: 6 Jun 17
Utility
Truncated epiderimal growth factor receptor (EGFRt) for transduced T cell selection
26 Oct 21
A non-immunogenic selection epitope may be generated by removing certain amino acid sequences of the protein.
Michael C. Jensen
Filed: 15 Oct 18